Cassava Sciences Inc SAVA shares are rising in extended trading Wednesday in the wake of recent insider buying.
The Details: According to a new regulatory filing, director Richard Barry recently purchased a total of 88,841 shares of Cassava Sciences at prices ranging from $25.51 to $26.20 per share.
Barry bought about 11,500 shares on Monday for an average price of $26.13 per share and then bought an additional 77,276 shares for an average price of $25.76 per share on Tuesday.
Notably, HC Wainwright & Co analyst Vernon Bernardino reiterated Cassava with a Buy rating and a price target of $124 this week.
Did You Know Benzinga Tracks Insider Trading? See Recent Trades Here.
Cassava Sciences is a clinical-stage biotechnology company focused on Alzheimer's disease.
SAVA Price Action: Cassava has a 52-week high of $51.59 and a 52-week low of $13.84.
The stock was up 9.89% after hours at $27.44 at time of publication, according to Benzinga Pro.
Photo: Gerd Altmann from Pixabay.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.